ENGINE

Engine Biosciences is a venture-backed biotechnology company that integrates high-throughput experimental biology with artificial intelligence to accelerate drug discovery. The company's proprietary platforms, NetMAP and CombiGEM, allow for the rapid mapping of gene interactions and the identification of synthetic lethal targets in complex diseases. Engine focuses on developing precision medicines, primarily in oncology, by targeting specific genetic vulnerabilities in cancer cells. With operations in Singapore and the United States, the company collaborates with leading academic institutions and pharmaceutical partners to advance its pipeline of small molecule therapeutics. Their lead program, ENB-812, targets PKMYT1 and is currently in IND-enabling studies for the treatment of solid tumors.